Clinical Trial Update: Study the Efficacy and Safety of the INtegral Cognitive REMediation Program (INCREM) for Depression [Phase 3]

View source ↗

Summary

Study evaluates the efficacy and safety of the INtegral Cognitive REMediation Program (INCREM) for depression in a Phase 3 trial. Recruitment is ongoing.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Depressive Disorder
• Major Depressive Disorder

Drugs mentioned

• INtegral Cognitive REMediation Program (INCREM)

Snippet

Sponsor: Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau | Conditions: Depression, Depressive Disorder | Phase 3 | Status: RECRUITING